current recommendations and future perspectives
Dunja Urbančič (Author), Flaka Pasha (Author), Alenka Šmid (Author), Irena Mlinarič-Raščan (Author)

Abstract

Despite great therapeutic advances in the field of biologics, small synthetic molecules such as thiopurines, including azathioprine, mercaptopurine, and thioguanine, remain an important therapeutic pillar in the treatment of inflammatory bowel disease, other autoimmune disorders, and cancer. This review presents the latest guidelines for thiopurine administration, highlighting the importance of individualized therapy guided by pharmacogenomics. It emphasizes dose adjustment based on nudix hydrolase 15 (NUDT15) and thiopurine S-methyltransferase (TPMT) genotype, alongside thiopurine S-methyltransferase activity and thiopurine metabolic profile. In addition, the article takes a critical look at emerging research in the field of thiopurine pharmacogenomics featuring novel genetic markers and technological developments in genetic testing. Finally, the potential of integrated approaches that combine genetic, metabolic, and clinical factors to further individualize thiopurine therapy is highlighted.

Keywords

thiopurines;TPMT;NUDT15;personalized medicine;therapeutic drug monitoring;

Data

Language: English
Year of publishing:
Typology: 1.02 - Review Article
Organization: UL FFA - Faculty of Pharmacy
UDC: 61-027.552
COBISS: 206023171 Link will open in a new window
ISSN: 1846-9558
Views: 11
Downloads: 0
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: Slovenian
Secondary keywords: tiopurini;TPMT;NUDT15;terapevtsko spremljanje zdravil;Personalizirana medicina;NUK;
Type (COBISS): Article
Pages: str. 355-381
Volume: ǂVol. ǂ74
Issue: ǂno. ǂ3
Chronology: 2024
DOI: 10.2478/acph-2024-0030
ID: 25250388